Colleen L Lau1, Kelley Meder1, Helen J Mayfield1, Therese Kearns2, Brady McPherson1, Take Naseri3, Robert Thomsen3, Shannon M Hedtke4, Sarah Sheridan5, Katherine Gass6, Patricia M Graves7. 1. Research School of Population Health, Australian National University, Canberra, Australia. 2. Menzies School of Health Research, Charles Darwin University, Brisbane, Australia. 3. Ministry of Health, Apia, Samoa. 4. Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, Victoria, Australia. 5. School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. 6. Neglected Tropical Diseases Support Center, The Task Force for Global Heath, Decatur, Georgia, United States of America. 7. College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Queensland, Australia.
Abstract
BACKGROUND: Samoa conducted eight nationwide rounds of mass drug administration (MDA) for lymphatic filariasis (LF) between 1999 and 2011, and two targeted rounds in 2015 and 2017 in North West Upolu (NWU), one of three evaluation units (EUs). Transmission Assessment Surveys (TAS) were conducted in 2013 (failed in NWU) and 2017 (all three EUs failed). In 2018, Samoa was the first in the world to distribute nationwide triple-drug MDA using ivermectin, diethylcarbamazine, and albendazole. Surveillance and Monitoring to Eliminate LF and Scabies from Samoa (SaMELFS Samoa) is an operational research program designed to evaluate the effectiveness of triple-drug MDA on LF transmission and scabies prevalence in Samoa, and to compare the usefulness of different indicators of LF transmission. This paper reports results from the 2018 baseline survey and aims to i) investigate antigen (Ag) prevalence and spatial epidemiology, including geographic clustering; ii) compare Ag prevalence between two different age groups (5-9 years versus ≥10 years) as indicators of areas of ongoing transmission; and iii) assess the prevalence of limb lymphedema in those aged ≥15 years. METHODS: A community-based cluster survey was conducted in 30 randomly selected and five purposively selected clusters (primary sampling units, PSUs), each comprising one or two villages. Participants were recruited through household surveys (age ≥5 years) and convenience surveys (age 5-9 years). Alere Filariasis Test Strips (FTS) were used to detect Ag, and prevalence was adjusted for survey design and standardized for age and gender. Adjusted Ag prevalence was estimated for each age group (5-9, ≥10, and all ages ≥5 years) for random and purposive PSUs, and by region. Intraclass correlation (ICC) was used to quantify clustering at regions, PSUs, and households. RESULTS: A total of 3940 persons were included (1942 children aged 5-9 years, 1998 persons aged ≥10 years). Adjusted Ag prevalence in all ages ≥5 years in randomly and purposively selected PSUs were 4.0% (95% CI 2.8-5.6%) and 10.0% (95% CI 7.4-13.4%), respectively. In random PSUs, Ag prevalence was lower in those aged 5-9 years (1.3%, 95% CI 0.8-2.1%) than ≥10 years (4.7%, 95% CI 3.1-7.0%), and poorly correlated at the PSU level (R-square = 0.1459). Adjusted Ag prevalence in PSUs ranged from 0% to 10.3% (95% CI 5.9-17.6%) in randomly selected and 3.8% (95% CI 1.3-10.8%) to 20.0% (95% CI 15.3-25.8%) in purposively selected PSUs. ICC for Ag-positive individuals was higher at households (0.46) compared to PSUs (0.18) and regions (0.01). CONCLUSIONS: Our study confirmed ongoing transmission of LF in Samoa, in accordance with the 2017 TAS results. Ag prevalence varied significantly between PSUs, and there was poor correlation between prevalence in 5-9 year-olds and older ages, who had threefold higher prevalence. Sampling older age groups would provide more accurate estimates of overall prevalence, and be more sensitive for identifying residual hotspots. Higher prevalence in purposively selected PSUs shows local knowledge can help identify at least some hotspots.
BACKGROUND: Samoa conducted eight nationwide rounds of mass drug administration (MDA) for lymphatic filariasis (LF) between 1999 and 2011, and two targeted rounds in 2015 and 2017 in North West Upolu (NWU), one of three evaluation units (EUs). Transmission Assessment Surveys (TAS) were conducted in 2013 (failed in NWU) and 2017 (all three EUs failed). In 2018, Samoa was the first in the world to distribute nationwide triple-drug MDA using ivermectin, diethylcarbamazine, and albendazole. Surveillance and Monitoring to Eliminate LF and Scabies from Samoa (SaMELFS Samoa) is an operational research program designed to evaluate the effectiveness of triple-drug MDA on LF transmission and scabies prevalence in Samoa, and to compare the usefulness of different indicators of LF transmission. This paper reports results from the 2018 baseline survey and aims to i) investigate antigen (Ag) prevalence and spatial epidemiology, including geographic clustering; ii) compare Ag prevalence between two different age groups (5-9 years versus ≥10 years) as indicators of areas of ongoing transmission; and iii) assess the prevalence of limb lymphedema in those aged ≥15 years. METHODS: A community-based cluster survey was conducted in 30 randomly selected and five purposively selected clusters (primary sampling units, PSUs), each comprising one or two villages. Participants were recruited through household surveys (age ≥5 years) and convenience surveys (age 5-9 years). Alere Filariasis Test Strips (FTS) were used to detect Ag, and prevalence was adjusted for survey design and standardized for age and gender. Adjusted Ag prevalence was estimated for each age group (5-9, ≥10, and all ages ≥5 years) for random and purposive PSUs, and by region. Intraclass correlation (ICC) was used to quantify clustering at regions, PSUs, and households. RESULTS: A total of 3940 persons were included (1942 children aged 5-9 years, 1998 persons aged ≥10 years). Adjusted Ag prevalence in all ages ≥5 years in randomly and purposively selected PSUs were 4.0% (95% CI 2.8-5.6%) and 10.0% (95% CI 7.4-13.4%), respectively. In random PSUs, Ag prevalence was lower in those aged 5-9 years (1.3%, 95% CI 0.8-2.1%) than ≥10 years (4.7%, 95% CI 3.1-7.0%), and poorly correlated at the PSU level (R-square = 0.1459). Adjusted Ag prevalence in PSUs ranged from 0% to 10.3% (95% CI 5.9-17.6%) in randomly selected and 3.8% (95% CI 1.3-10.8%) to 20.0% (95% CI 15.3-25.8%) in purposively selected PSUs. ICC for Ag-positive individuals was higher at households (0.46) compared to PSUs (0.18) and regions (0.01). CONCLUSIONS: Our study confirmed ongoing transmission of LF in Samoa, in accordance with the 2017 TAS results. Ag prevalence varied significantly between PSUs, and there was poor correlation between prevalence in 5-9 year-olds and older ages, who had threefold higher prevalence. Sampling older age groups would provide more accurate estimates of overall prevalence, and be more sensitive for identifying residual hotspots. Higher prevalence in purposively selected PSUs shows local knowledge can help identify at least some hotspots.
Authors: Katherine Gass; Madsen V E Beau de Rochars; Daniel Boakye; Mark Bradley; Peter U Fischer; John Gyapong; Makoto Itoh; Nese Ituaso-Conway; Hayley Joseph; Dominique Kyelem; Sandra J Laney; Anne-Marie Legrand; Tilaka S Liyanage; Wayne Melrose; Khalfan Mohammed; Nils Pilotte; Eric A Ottesen; Catherine Plichart; Kapa Ramaiah; Ramakrishna U Rao; Jeffrey Talbot; Gary J Weil; Steven A Williams; Kimberly Y Won; Patrick Lammie Journal: PLoS Negl Trop Dis Date: 2012-01-17
Authors: Kimberly Y Won; Keri Robinson; Katy L Hamlin; Joseph Tufa; Margaret Seespesara; Ryan E Wiegand; Katherine Gass; Joseph Kubofcik; Thomas B Nutman; Patrick J Lammie; Saipale Fuimaono Journal: PLoS Negl Trop Dis Date: 2018-03-09
Authors: Helen J Mayfield; Hugh Sturrock; Benjamin F Arnold; Ricardo Andrade-Pacheco; Therese Kearns; Patricia Graves; Take Naseri; Robert Thomsen; Katherine Gass; Colleen L Lau Journal: Sci Rep Date: 2020-11-25 Impact factor: 4.379
Authors: Ramakrishna U Rao; Sandhya D Samarasekera; Kumara C Nagodavithana; Manjula W Punchihewa; Tharanga D M Dassanayaka; Gamini P K D; Ethan Ford; Udaya S B Ranasinghe; Ralph H Henderson; Gary J Weil Journal: PLoS Negl Trop Dis Date: 2016-05-19
Authors: Samuel O Asiedu; Priscilla Kini; Bill C Aglomasa; Emmanuel K A Amewu; Ebenezer Asiedu; Solomon Wireko; Kennedy G Boahen; Afiat Berbudi; Augustina A Sylverken; Alexander Kwarteng Journal: Health Sci Rep Date: 2022-07-20
Authors: Patricia M Graves; Sarah Sheridan; Jessica Scott; Filipina Amosa-Lei Sam; Take Naseri; Robert Thomsen; Christopher L King; Colleen L Lau Journal: Trop Med Infect Dis Date: 2021-04-01
Authors: Brady McPherson; Helen J Mayfield; Angus McLure; Katherine Gass; Take Naseri; Robert Thomsen; Steven A Williams; Nils Pilotte; Therese Kearns; Patricia M Graves; Colleen L Lau Journal: Trop Med Infect Dis Date: 2022-08-22
Authors: Anna C Rivara; Margaret Corley; Courtney C Choy; Rachel L Duckham; Alysa Pomer; Muagututia Sefuiva Reupena; Satupaitea Viali; Take Naseri; Erin E Kershaw; Scott E Crouter; Stephen T McGarvey; Richard G Bribiescas; Claudia Valeggia; Nicola L Hawley Journal: Am J Hum Biol Date: 2021-07-14 Impact factor: 1.937